Advocacy Actions
Comments to State Administration for Market Regulation (SAMR) on the Anti-unfair Competition Law (Revised draft for comments)
European Chamber submitted comments to State Adminstration for Market Regulation (SAMR) on the Anti-unfair Competition Law of the People's Republic of China (Revised Draft for Comment), on 21st December 2022.
Read moreComments to China National Intellectual Property Administration (CNIPA) on the Patent Examination Guidelines (Revised draft for comment)
On 15th December, European Chamber IPR Working Group submitted comments to China National Intellectual Property Administration (CNIPA) on the Patent Examination Guidelines (Revised draft for comments).
Read moreComments to the National Medical Products Administration (NMPA) on the Provisions on Supervision and Administration of the Subject Responsibility for the Implementation of Drug Quality by Drug Marketing Authorisation Holders (Draft for Comments)
On 9th December, European Chamber Pharmaceutical Working Group submitted comments to the National Medical Products Administration (NMPA) on the Provisions on Supervision and Administration of the Subject Responsibility for the Implementation of Drug Quality by Drug Marketing Authorisation Holders (Draft for Comments).
Read moreEuropean Chamber Co-organises EU-China Biopharmaceutical Innovation and Development Roundtable
On 24th November 2022, the EU-China Biopharmaceutical Innovation and Development Roundtable took place using a hybrid format connecting Beijing and Brussels.
The roundtable, co-organised by the European Chamber and the China Society for Drug Regulation (CSDR), with the support from the European Federation of Pharmaceutical Industries and Associations (EFPIA), enabled an open dialogue on pro-innovation regulatory policies between representatives from the European pharmaceutical industry and the National Medical Products Administration (NMPA).
European Chamber Attended CCPIT 2022 Third-quarter Roundtable with Foreign Businesses
On 9th September, European Chamber attended the quarterly online roundtable with foreign chambers and enterprises for the third quarter of 2022, hosted by the Department of Development Research of the China Council for the Promotion of International Trade (CCPIT).
Comments to State Administration for Market Regulation (SAMR) on the Prohibition of Abuse of Intellectual Property Rights to Exclude or Restrict Competition (Draft for Comments)
On 27th July, the European Chamber submitted comments to State Administration for Market Regulation (SAMR) on the Prohibition of Abuse of Intellectual Property Rights to Exclude or Restrict Competition (Draft for Comments).
Read moreNMPA Forum on Regulatory Science and International Harmonisation of Traditional Medicines
The National Medical Product Administration (NMPA) organised the first international forum on regulatory strategies to ensure safety and efficacy of tradional and natural medicines.
Read moreGreeting Remarks at the China-European Cooperation Platform for Life Science and Healthcare in Germany
The China Investment Promotion Agency of the Chinese Ministry of Commerce in cooperation with the Department of Commerce of Zhenjiang Province and the City Government of Hangzhou organised a matchmaking meeting between Chinese and German companies from the life science and healthcare sector.
Read moreComments to National Healthcare Security Administration (NHSA) on 2022 National Reimbursement Drug List (NRDL) Adjustment Workplan and Other Documents
On 19th June, European Chamber Pharmaceutical Working Group submitted comments to the National Healthcare Security Administration (NHSA) on the 2022 National Reimbursement Drug List (NRDL) Adjustment Workplan, 2022 NRDL Adjustment Application Guideline, and the Negotiating Rules for Renewal Drugs.
Read moreComments to National Medical Products Administration (NMPA) on the Implementation Regulations of Drug Administration Law (Draft Revisions))
European Chamber submitted a 60-page long comment to the National Medical Products Administration (NMPA) on the Implementation Regulations of the Drug Administration Law of the People's Republic of China (Draft Revisions) on 9th June.